Aptar Digital Health Expands Oncology Clinical Advisory Board

Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, today announced the expansion of its Oncology Clinical Advisory Board. Comprised of leading clinical, oncology and digital experts from across a wide range of cancer specialties, this newly formed Clinical Advisory Board will help provide critical review and scientific guidance to Aptar Digital Health on the development of its evidence-based medical algorithms.

The new members of the Aptar Digital Health Oncology Clinical Advisory Board include:

  1. Adam DICKER, MD, PhD – Chair and Professor of Radiation Oncology, Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
  2. Marilyn HUANG, MD – Professor of Gynecologic Oncology, Director of Translational Gynecologic Oncology Research, University of Miami, Miami, FL
  3. Mario LACOUTURE, MD – Director of the Oncodermatology Program, Memorial Sloan Kettering Cancer Center, New York, NY
  4. Aditi U. JOSHI, MD, MSc – Emergency Medicine Physician, Telehealth and Digital Health Expert, US.

These members are welcomed by existing members of the Board, including:

Paolo BOSSI, MD, Prof. – Associate Professor, Medical Oncology, University of Brescia and ASST Spedali Civili, Brescia, Italy

Karin JORDAN, MD, Prof. – Head of Department of Hematology, Oncology and Palliative Care​, Ernst von Bergmann Clinic, Potsdam, Germany ​
Matti AAPRO, MD – Dean of Multidisciplinary Oncology Institute, Genolier Cancer Centre Switzerland

Guido CAVALETTI, MD – Head of the Neuroimmunology Center, S. Gerardo Hospital, Monza, Italy

Gregory LIP, MD – Cardio-Oncology Expertise, Liverpool Heart & Chest Hospital, Liverpool, UK.

Pere GASCON, MD, PhD – Chief of Medical Oncology and Scientific Coordinator, Hospital Clínic, Barcelona, Spain.

“We are pleased to strengthen our Clinical Advisory Board and to welcome our new members,” commented Pierre Leurent, President, Aptar Digital Health. “Their broad medical expertise will allow us to have a deeper knowledge and expand our global vision of the clinical practice for multiple types of cancer.”

Genevieve D’Orsay, MD, Chief Medical Officer at Aptar Digital Health added, “The Clinical Advisory Board contributes to the design of our clinical algorithms that support patients in the management of treatment-related symptoms. The contribution of each member is key to ensuring our solutions address a clinical need. Our Advisory Board also guides Aptar Digital Health in our clinical strategy decision, including the deployment of clinical studies.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version